Page 140 - 2019年9月第30卷第17期

华医学电子音像出版社，2015：45-92. hances the activity of frontocortical dopaminergic and ad-
[13] FERRARI F，VILLA RF. The neurobiology of depres- renergic pathways[J]. J Pharm Exp Ther，2003，306（3）：
sion ：an integrated overview from biological theories to 954-964.
clinical evidence[J]. Mol Neurobiol，2017，54（7）：4847- [28] GUARDIOLA-LEMAITRE B，DEBODINAT C，DELA-
4865. GRANGE P，et al. Agomelatine：mechanism of action and
[14] ADAMSAMUEL SB，LEONARDO ED，HEN R. Hippo- pharmacological profile inrelation to antidepressant prop-
campal subfields and major depressive disorder[J]. Biol erties[J]. Br J Pharmacol，2014，171（15）：3604-3619.
Psychiatry，2015，77（3）：210-211. [29] STAHL SM. Mechanism of action of agomelatine：a novel
[15] SCHOENFELD TJ，MCCAUSLAND HC，MORRIS HD， antidepressant exploiting synergy between monoaminer-
et al. Stress and loss of adult nurogenesis differentially re- gic and melatonergicproperties[J]. CNS Spectr，2014，19
duce hippocampal volume[J]. Bioll Psychiatry，2017，82 （3）：207-212.
（12）：914-923. [30] DEBODINAT C，GUARDIOLA-LEMAITRE B，MOCA-
[16] HILL AS，SAHAY A，HEN R. Increasing adult hippocam- ER E，et al. Agomelatine，the first melatonergic antidepres-
pal neurogenesis is sufficient to reduce anxiety and depres- sant：discovery，characterizationand development[J]. Nat
sionlike behaviors[J]. Neuropsychopharmacology，2015， Rev Drug Discov，2010，9（8）：628-642.
40（10）：2368-2378. [31] POMPILI M，SERAFINI G，INNAMORATI M，et al.
[17] MORAITIS AG，BLOCK T，NGUYEN D，et al. The role Agomelatine，a novel intriguing antidepressant option en-
of glucocorticoid receptors in metabolic syndrome and hancing neuroplasticity：a critical review[J]. World J Biol
psychiatric illness[J]. J Steroid Biochem Mol Biol，2017. Psychiatry，2013，14（6）：412-431.
DOI：10.1016/j.jsbmb.2016.03.023. [32] TARDITO D，MOLTENI R，POPOLIM，et al. Synergistic
[18] 张国双，杨坤.抗抑郁新靶点：糖皮质激素受体[J].国际精 mechanisms involved in theantidepressant effects of
神病学杂志，2015，42（1）：84-86. agomelatine[J]. Eur Neuropsychopharmacol，2012.DOI：
[19] KINLEIN SA，WILSON CD，KARATSOREOS IN. Dys- 10.1016/j.euroneuro.2012.06.016.
regulated hypothalamic-pituitary-adrenal axis function [33] KENNEDY SH，AVEDISOVA A，GIMÉNEZ-MONTESI-
contributes to altered endocrine and neurobehavioral re- NOS N，et al. A placebo-controlled study of three agomela-
sponses to acute stress[J]. Front Psychiatry，2015.DOI： tine dose regimens（10 mg，25 mg，25-50 mg）in patients
10.3389/fpsyt.2015.00031. with major depressive disorder[J]. Eur Neuropsychophar-
[20] ZHUANG F，ZHOU X，GAO X，et al. Cytokines and glu- macol，2014，24（4）：553-563.
cocorticoid receptors are associated with the antidepres- [34] SIDNEY H，KENNEDY SH，ALLA-AVEDISOVA，et al.
sant-like effect of alarin[J]. Peptides，2016.DOI：10.1016/j. Sustained efficacy of agomelatine 10 mg，25 mg，and
peptides.2016.01.002. 25-50 mg on depressive symptoms and functional out-
[21] FELGER JC，LOTRICH FE. Inflammatory cytokines in comes in patient with major depressive disorder. a place-
depression：neurobiological mechanisms and therapeutic bo-controlled study over 6 months[J]. Eur Neuropsycho-
implications[J]. Neuroscience，2013，246（5）：199-229. pharmacol，2016，26（2）：378-389.
[22] SU WJ，CAO ZY，JIANG CL. Inflammatory mechanism [35] HEUN R，AHOKAS A，BOYER P，et al. The efficacy of
of depression and its new strategy for diagnosis and treat- agomelatine in elderly patients with recurrent major de-
ment[J]. Sheng Li Xue Bao，2017，69（5）：715-722. pressive disorder：a placebo-controlled study[J]. J Clin
[23] 汪崇泽，盛国红.免疫炎症途径与抑郁症的研究进展[J]. Psychiatry，2013，74（6）：587-594.
精神医学杂志，2015，28（5）：397-400. [36] UDRISTOIU T，DEHELEAN P，NUSS P，et al. Early
[24] RANTAMAKI T，YALCIN I. Antidepressant drug action- effect on general interest，and short-term antidepressant
from rapid changes on network function to network rewir- efficacy and safety of agomelatine（25-50 mg/day）and
ing[J]. Prog Neuropsychopharmacol Biol Psychiatry， escitalopram（10-20 mg/day）in outpatients with major
2016.DOI：10.1016/j.pnpbp.2015.06.001. depressive disorder. a 12-week randomised double-blind
[25] SCHMITT K，HOLSBOER-TRACHSLER E，ECKERT A. comparative study[J]. J Affect Disord，2016，199（15）：
BDNF in sleep ，insomnia ，and sleep deprivation[J]. Ann 6-12.
Med，2016，48（1/2）：42-51. [37] 杨丹.阿戈美拉汀与草酸艾司西酞普兰治疗抑郁症的对
[26] 黄良峰，陈洋洋，赵炳功，等.抑郁症的成因及其新药治疗 照研究[J].中国现代药物应用，2018，12（19）：136-137.
研究进展[J].现代生物医学进展，2018，18（1）：180-185. [38] 夏传红.阿戈美拉汀与帕罗西汀治疗首发抑郁症对照研
[27] MILLAN MJ，GOBERT A，LEJEUNE F，et al. The novel 究[J].山东医学高等专科学校学报，2017，39（1）：40-42.
melatonin agonistagomelatine（S20098）is an antagonist at [39] 姜海军，苏金哥.研究阿戈美拉汀与帕罗西汀治疗首发抑
5-hydroxytryptamine-2C receptors，blockade of which en- 郁症的效果[J].数理医药学杂志，2018，31（5）：759-760.

中国药房 2019年第30卷第17期 China Pharmacy 2019 Vol. 30 No. 17 ·2439 ·